CA
NZ
UK
AU
IND
US
Ping An Biomedical Co. Ltd. (NASDAQ: PASW) reported total assets of RMB100,222,250 at March 31, 2026, compared with RMB68,414,527 in the earlier balance-sheet column. The first-half 2026 unaudited financial results also showed total current assets of RMB55,910,772 and total non-current assets of RMB44,311,478. The …
The first-in-human trial will evaluate the candidate in adults with locally advanced or metastatic disease.
The designation applies to the company’s lead asset and addresses a condition for which the company says there are currently no approved treatments.
REGENTIS BIOMATERIALS LTD. (AMEX: RGNT) (AMEX: RGNT) reported a $2.6 million net loss for the six months ended June 30, 2026. The clinical-stage company had $8.952 million in cash and cash equivalents at June 30, 2026, against $1.669 million in total liabilities. Its interim …
Relmada Therapeutics, Inc. (NASDAQ: RLMD) Chief Executive Officer Sergio Traversa bought 200,000 shares across two transactions priced from $4.10 to $4.18 per share. The purchases left Traversa with 1,500,000 shares.
SCYNEXIS INC (NASDAQ: SCYX) appointed Sanjay Subramanian as chief financial officer effective September 9, with an annual base salary of $500,000. He will also serve as the company’s principal financial officer and principal accounting officer. Ivor Macleod, who previously held those roles, is retiring …
KALA BIO, Inc. (NASDAQ: KALA) has exclusive U.S. rights to distribute and resell Virotek’s ophthalmology genetic testing and screening program until a September 3, 2027 milestone determines whether that status continues. The arrangement covers genetic testing and clinical screening and began on September 3, …
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is expected to issue 20,000 shares of preferred stock to pay $20.0 million in fees owed to certain consenting parties. The arrangement gives Karyopharm additional time to advance its myelofibrosis program, negotiate with lenders, pursue strategic alternatives or complete …
Lipocine (NASDAQ: LPCN) Sets September 16 Conference
Lyell Immunopharma, Inc. (NASDAQ: LYEL) completed the technology transfer of LYL273 to its LyFE Manufacturing Center in Bothell, Washington, while updating the expected timing for additional trial data and an End-of-Phase 1 FDA meeting to 2027.
Please wait processing your request...